Pancreatic Cancer Research

ResearcherJohns Hopkins UniversityActive in the last 2 years

Lingdi Yin

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-1432-4626; OpenAlex author ID A5030565805. Sources: OpenAlex.

Their work

Papers
24 (first author 1, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
70
Papers, trials and grants by year

2016: 1 paper · 2017: 2 papers · 2018: 2 papers · 2019: 3 papers · 2020: none · 2021: 5 papers · 2022: 4 papers · 2023: none · 2024: 1 paper · 2025: 4 papers · 2026: 2 papers

Papers 24

  1. An Insulin-Exosome-TNFAIP8 Axis Drives Stromal Fibrosis and Therapeutic Resistance in Pancreatic Cancer. Co-author DOI 10.1002/advs.202515606↗
  2. Co-evolution of Oncogenic KRAS Signaling and LILRB high Macrophages Drives Pancreatic Cancer Recurrence Co-author DOI 10.64898/2026.03.05.709991↗
  3. LIM domain only 7: a novel driver of immune evasion through regulatory T cell differentiation and chemotaxis in pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41418-024-01358-7↗
  4. USP19 potentiates autophagic cell death via inhibiting mTOR pathway through deubiquitinating NEK9 in pancreatic cancer. Co-author DOI 10.1038/s41418-024-01426-y↗
  5. Correction: A Yin-Yang 1/miR-30a regulatory circuit modulates autophagy in pancreatic cancer cells. Co-author DOI 10.1186/s12967-025-06581-5↗
  6. Development and Validation of a Cell-Free DNA Fragmentomics-Based Model for Early Detection of Pancreatic Cancer. Co-author DOI 10.1200/jco.24.00287↗
  7. High pyroptosis activity in pancreatic adenocarcinoma: poor prognosis and oxaliplatin resistance. Co-author DOI 10.1007/s10495-023-01901-w↗
  8. Prevalence of Germline Sequence Variations Among Patients With Pancreatic Cancer in China. Co-author DOI 10.1001/jamanetworkopen.2021.48721↗
  9. A histopathological study of artery wall involvement in pancreatic cancer surgery. Co-author DOI 10.1007/s00423-022-02689-0↗
  10. The distinct genetic features of pancreatic cancer in Chinese population. Co-author DOI 10.1016/j.ebiom.2022.103960↗
  11. Pathological treatment response has different prognostic implications for pancreatic cancer patients treated with neoadjuvant chemotherapy or chemoradiotherapy. Co-author DOI 10.1016/j.surg.2021.10.015↗
  12. Sub-adventitial divestment technique for resecting artery-involved pancreatic cancer: a retrospective cohort study. Co-author DOI 10.1007/s00423-021-02080-5↗
  13. Reliable Detection of Somatic Mutations for Pancreatic Cancer in Endoscopic Ultrasonography-Guided Fine Needle Aspirates with Next-Generation Sequencing: Impli… Co-author DOI 10.1007/s11605-021-05078-y↗
  14. Improved Assessment of Response Status in Patients with Pancreatic Cancer Treated with Neoadjuvant Therapy using Somatic Mutations and Liquid Biopsy Analysis. Co-author DOI 10.1158/1078-0432.ccr-20-1746↗
  15. Opposite Roles of Tumor Cell Proliferation and Immune Cell Infiltration in Postoperative Liver Metastasis of PDAC. Co-author DOI 10.3389/fcell.2021.714718↗
  16. CA9-Related Acidic Microenvironment Mediates CD8+ T Cell Related Immunosuppression in Pancreatic Cancer. Co-author DOI 10.3389/fonc.2021.832315↗
  17. Central pancreatectomy for early-stage pancreatic ductal adenocarcinoma: a single-center case-control study. Co-author DOI 10.1007/s00423-019-01766-1↗
  18. Genetic landscape of prognostic value in pancreatic ductal adenocarcinoma microenvironment. Co-author DOI 10.21037/atm.2019.10.91↗
  19. Optimized modification of the eighth edition of AJCC TNM staging system for resected pancreatic ductal adenocarcinoma. First author DOI 10.2217/fon-2019-0264↗
  20. Thymidine kinase 1 silencing retards proliferative activity of pancreatic cancer cell via E2F1-TK1-P21 axis. Co-author DOI 10.1111/cpr.12428↗
  21. PIK3R3 Promotes Metastasis of Pancreatic Cancer via ZEB1 Induced Epithelial-Mesenchymal Transition. Co-author DOI 10.1159/000489382↗
  22. A Yin-Yang 1/miR-30a regulatory circuit modulates autophagy in pancreatic cancer cells. Co-author DOI 10.1186/s12967-017-1308-3↗
  23. PEG10 overexpression induced by E2F-1 promotes cell proliferation, migration, and invasion in pancreatic cancer. Co-author DOI 10.1186/s13046-017-0500-x↗
  24. Altered expression of CD226 and CD96 on natural killer cells in patients with pancreatic cancer. Co-author DOI 10.18632/oncotarget.11953↗

Closest collaborators

The 25 strongest of 70 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Yi Miao · 18 shared papers, 2016–2026 · strength 2.52
  2. Kuirong Jiang · 13 shared papers, 2017–2026 · strength 1.97
  3. Jishu Wei · 13 shared papers, 2016–2026 · strength 1.75
  4. Zipeng Lu · 10 shared papers, 2021–2025 · strength 1.63
  5. Yunpeng Peng · 10 shared papers, 2016–2025 · strength 1.19
  6. Min Tu · 7 shared papers, 2018–2026 · strength 1.01
  7. Wentao Gao · 8 shared papers, 2017–2025 · strength 0.98
  8. Guangfu Wang · 5 shared papers, 2019–2025 · strength 0.86
  9. Jun Yu · 6 shared papers, 2019–2026 · strength 0.85
  10. Junli Wu · 6 shared papers, 2019–2025 · strength 0.80
  11. Shangnan Dai · 4 shared papers, 2021–2025 · strength 0.78
  12. Chunhua Xi · 5 shared papers, 2016–2026 · strength 0.64
  13. Ning Pu · 4 shared papers, 2019–2025 · strength 0.51
  14. Jingjing Zhang · 4 shared papers, 2016–2025 · strength 0.45
  15. Hao Gao Gao · 3 shared papers, 2019–2022 · strength 0.34
  16. Chuang Yang · 2 shared papers, 2017–2025 · strength 0.33
  17. Kai Zhang · 3 shared papers, 2019–2022 · strength 0.32
  18. Qiang Li · 3 shared papers, 2018–2022 · strength 0.31
  19. Yayun Zhu · 3 shared papers, 2019–2021 · strength 0.29
  20. Jian‐Min Chen · 2 shared papers, 2022–2025 · strength 0.29
  21. Qiuyang Chen · 2 shared papers, 2018–2025 · strength 0.29
  22. Christopher Lee Wolfgang · 2 shared papers, 2021 · strength 0.27
  23. Markus Wolfgang Büchler · 2 shared papers, 2021–2022 · strength 0.25
  24. Baobao Cai · 2 shared papers, 2021–2022 · strength 0.25
  25. John P. Neoptolemos · 2 shared papers, 2021–2022 · strength 0.25

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.